Synergy of intercalation and coordination binding to design novel DNA-targeting antineoplastic metallodrugs
Roy, Sudeshna
Citation
Roy, S. (2008, November 25). Synergy of intercalation and coordination binding to design novel DNA-targeting antineoplastic metallodrugs. Retrieved from
https://hdl.handle.net/1887/13281
Version: Corrected Publisher’s Version
License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/13281
Note: To cite this publication please use the final published version (if applicable).
Stellingen
behorende bij het proefschrift
Synergy of intercalation and coordination binding to design novel DNA- targeting antineoplastic metallodrugs
Sudeshna Roy
1. Combination of two different toxins does not always yield a severe toxic agent.
(this thesis)
2. The change in aromaticity of phenanthroline derivatives affects the cytotoxic property to a significant extent.
(this thesis)
3. There is no straightforward correlation between DNA-binding and in vitro antiproliferative activity.
(this thesis)
4. Dinuclear transition-metal compounds demand detailed and in depth research for understanding their cellular processing.
(this thesis)
5. A proper understanding of the reasons for a compound’s biological inactivity may shed light on how to generate active analogues.
(this thesis)
6. Lipinski’s rule of five can enhance the likelihood of a designed molecule to be bioavailable and potential active medicine.
(Fricker, S. M., Dalton Trans., 2007, 4903-4917)
7. ‘Network targeting’ in complicated protein cascades may seem logical in idea;
however, synthesis of a multiple-targeting drug in chemical laboratory sets up a far-reached goal.
(Strebhardt, K.; Ullrich, A., Nature Rev., 2008, 8, 473-480)
8. Metastases are the leading causes of cancer death with solid human tumours and would deserve immediate attention by bioinorganic anticancer researchers.
(Bergamo, A.; Sava, G., Dalton Trans., 2007, 1267-1272)
9. The differences in the aim of preclinical studies and clinical trials are mutually incompatible and thus retard the development of new drugs.
(van Hoff, D. D., Clin. Cancer Res., 1998, 4, 1079-1086)
10. Design of a ‘smart drug’ requires multifaceted ideas; in reality most of the times the real ‘breakthrough’ comes from serendipitous discoveries.
11. Intense collaboration among chemist, molecular biologist, pharmacologist and medical practitioner might lead to a powerful battle against cancer.
12. Anticancer research is a luxury when common people suffer starvation death.
(context to underdeveloped and developing countries)
13. Embracing the good always wipes away the pain of going through hard part of life however, the time of transition varies for each individual.
25th November, 2008
______________
